RE: Successful in an Azactidine refractory patient5 Dec 2022 22:21
I was in NCYT Feb 2020 not many parallels in my opinion. I kept about 60% of my gains 9+ before the peak and then sold on the way down. NCYT had proven sales nothing huge, but failed to lock in the boom (a placing to cool the rise, locking in some of the hype for later). Covid testing fell off a cliff, direction has been sad ever since. FARN has golden egg products if they get to market, time scales and risks are hard to gauge from a private investor point of view though. I am hopeful, but have lost in the past. This has multiple products / treatment targets just needs wider trials, and deals longer term (note we do not have a positive cash flow).